Yiqi Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yiqi Zhu has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Ramkrishna Kumar Singh
Washington University School of Medicine
7 shared publications - Ganesh M. Babulal
Department of Neurology Mayo Clinic Rochester Minnesota USA
6 shared publications - Semere Bekena
Washington University School of Medicine
6 shared publications Ganesh M. Babulal
Department of Psychology Uvniversity of Johannesburg Johannesburg South Africa
3 shared publications- Jean-Francois Trani
Brown School, Washington University in St Louis, St Louis, MO, USA
3 shared publications Alexis I.B. Walker
Washington University School of Medicine, St Louis
2 shared publications
Latest Publications
- 2 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (4) , 1758-1771
Exploratory factor and network analysis of 43 inflammatory plasma biomarkers and cognitive performance in Black adults
Background: Systemic inflammation has been implicated in cognitive aging and neurodegeneration; however, inflammatory biomarkers are expressed in coordinated patterns rather than as isolated markers. Objective: To identify latent inflammatory biomarker groupings and evaluate their associations with cognitive performance among midlife and older adults. Methods: This cross-sectional study included 334 participants from the Aging Research Characterizing Health Exposome via Social Drivers (ARCHES) study. Cognitive performance was assessed using the Preclinical Alzheimer Cognitive Composite (PACC). Plasma inflammatory biomarkers were quantified using the NuLISA™ multiplex immunoassay platform. Exploratory factor analysis (EFA) (minimum residual extraction, oblimin rotation) identified latent inflammatory factors, retaining biomarkers with loadings ≥0.40. Factor scores were evaluated in multivariable linear regression models adjusted for age, sex, education, and genotype status; sensitivity analyses adjusted for socioeconomic context, medication use, BMI, lifestyle factors, and clinical diagnoses. Age-stratified and nonlinear spline analyses were conducted. Results: 27 of 43 biomarkers formed an eight-factor structure explaining 43% of variance. Two factors were significantly associated with cognitive performance after FDR correction. Factor 4 (CCL4, CXCL1, S100A12) and Factor 5 (IL2, IL5, IL13, IL10, CSF2) were inversely associated with PACC scores. These associations remained consistent across sensitivity analyses. Age-stratified analyses showed that several inflammatory factors were associated with cognitive performance among participants aged 45–<65 years, whereas no factors remained significant among participants aged ≥65 years after FDR correction. Nonlinear modeling indicated a non-linear age-cognitive performance relationship. Conclusions: EFA identified clusters of correlated inflammatory biomarkers associated with cognitive performance in this cohort of midlife and older adults.
- 2 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (4) , 1758-1771
Exploratory factor and network analysis of 43 inflammatory plasma biomarkers and cognitive performance in Black adults
Background: Systemic inflammation has been implicated in cognitive aging and neurodegeneration; however, inflammatory biomarkers are expressed in coordinated patterns rather than as isolated markers. Objective: To identify latent inflammatory biomarker groupings and evaluate their associations with cognitive performance among midlife and older adults. Methods: This cross-sectional study included 334 participants from the Aging Research Characterizing Health Exposome via Social Drivers (ARCHES) study. Cognitive performance was assessed using the Preclinical Alzheimer Cognitive Composite (PACC). Plasma inflammatory biomarkers were quantified using the NuLISA™ multiplex immunoassay platform. Exploratory factor analysis (EFA) (minimum residual extraction, oblimin rotation) identified latent inflammatory factors, retaining biomarkers with loadings ≥0.40. Factor scores were evaluated in multivariable linear regression models adjusted for age, sex, education, and genotype status; sensitivity analyses adjusted for socioeconomic context, medication use, BMI, lifestyle factors, and clinical diagnoses. Age-stratified and nonlinear spline analyses were conducted. Results: 27 of 43 biomarkers formed an eight-factor structure explaining 43% of variance. Two factors were significantly associated with cognitive performance after FDR correction. Factor 4 (CCL4, CXCL1, S100A12) and Factor 5 (IL2, IL5, IL13, IL10, CSF2) were inversely associated with PACC scores. These associations remained consistent across sensitivity analyses. Age-stratified analyses showed that several inflammatory factors were associated with cognitive performance among participants aged 45–<65 years, whereas no factors remained significant among participants aged ≥65 years after FDR correction. Nonlinear modeling indicated a non-linear age-cognitive performance relationship. Conclusions: EFA identified clusters of correlated inflammatory biomarkers associated with cognitive performance in this cohort of midlife and older adults.
- Open Access
- 26 August 2026
- Published by Wiley in Journal of the American Geriatrics Society
Driving Navigation in Older Adults Across the Alzheimer's Disease Continuum
Background and Objectives: To examine whether time from amyloid positivity (amyloid time), a continuous measure of biological Alzheimer's disease (AD) progression, is associated with differences in navigation‐related driving behaviors among older adults. Methods: This longitudinal cohort study was drawn from the DRIVES participants who had at least one PET Pittsburgh compound‐B (PiB) scan. AD timeline was assessed using amyloid time, estimated with the Sampled Iterative Local Approximation (SILA) approach. SILA aligns individuals relative to the timing of amyloid positivity. Naturalistic driving data were continuously collected using in‐vehicle data loggers. Navigation‐related behaviors were quantified using trip‐chaining and entropy metrics. Linear mixed‐effects models examined associations between amyloid time and longitudinal differences in trip chaining behaviors, adjusting for demographic factors. Growth mixture models were used to explore latent trajectory classes, and logistic regression was used to explore demographic characteristics, self‐reported medical history, and medication use as potential risk and resilience factors associated with membership in trajectory classes. Results: Greater amyloid time was associated with higher counts and proportions of chained trips and less entropy, indicating more predictable driving patterns over time. Growth mixture modeling identified two distinct trajectory classes for both trip chaining and entropy. Insomnia was associated with a faster increase in trip chaining, whereas psychiatric conditions, such as having a diagnosis of depression or anxiety, were associated with a slower decline in entropy. Discussion: Amyloid time is associated with gradual differences in real‐world navigation behaviors among cognitively normal older adults. More trip chaining and less entropy may reflect compensatory planning and reduced driving space in the context of early AD pathology. These findings highlight the utility of naturalistic driving data as ecologically valid, scalable markers of early functional change and underscore the importance of continuous biomarker measures for capturing disease progression prior to clinical symptom onset.
- 26 August 2026
- Published by Wiley in Journal of the American Geriatrics Society
Open AccessDriving Navigation in Older Adults Across the Alzheimer's Disease Continuum
Background and Objectives: To examine whether time from amyloid positivity (amyloid time), a continuous measure of biological Alzheimer's disease (AD) progression, is associated with differences in navigation‐related driving behaviors among older adults. Methods: This longitudinal cohort study was drawn from the DRIVES participants who had at least one PET Pittsburgh compound‐B (PiB) scan. AD timeline was assessed using amyloid time, estimated with the Sampled Iterative Local Approximation (SILA) approach. SILA aligns individuals relative to the timing of amyloid positivity. Naturalistic driving data were continuously collected using in‐vehicle data loggers. Navigation‐related behaviors were quantified using trip‐chaining and entropy metrics. Linear mixed‐effects models examined associations between amyloid time and longitudinal differences in trip chaining behaviors, adjusting for demographic factors. Growth mixture models were used to explore latent trajectory classes, and logistic regression was used to explore demographic characteristics, self‐reported medical history, and medication use as potential risk and resilience factors associated with membership in trajectory classes. Results: Greater amyloid time was associated with higher counts and proportions of chained trips and less entropy, indicating more predictable driving patterns over time. Growth mixture modeling identified two distinct trajectory classes for both trip chaining and entropy. Insomnia was associated with a faster increase in trip chaining, whereas psychiatric conditions, such as having a diagnosis of depression or anxiety, were associated with a slower decline in entropy. Discussion: Amyloid time is associated with gradual differences in real‐world navigation behaviors among cognitively normal older adults. More trip chaining and less entropy may reflect compensatory planning and reduced driving space in the context of early AD pathology. These findings highlight the utility of naturalistic driving data as ecologically valid, scalable markers of early functional change and underscore the importance of continuous biomarker measures for capturing disease progression prior to clinical symptom onset.
- 28 July 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (2) , 769-780
Hearing in noise and cognitive status in older adults: Biomarker associations and bidirectional survival analyses
Background: Hearing impairment (HI) has been identified as a potentially modifiable risk factor for dementia, yet its relationship with Alzheimer's disease (AD) neuropathology and the temporal directionality remain unclear, particularly in late life. Objective: To examine cross-sectional and longitudinal associations between HI, clinical cognitive status, and AD biomarkers in community-dwelling older adults. Methods: We included 474 DRIVES Project participants (mean age 73.5 ± 5.2 years). Hearing was assessed using the NIH Toolbox Words-in-Noise (WIN) test. Clinical cognitive status was assessed using Clinical Dementia Rating (CDR). AD biomarkers included cerebrospinal fluid (CSF) Aβ 42 /Aβ 40 , t-tau/Aβ 42 , and p-tau/Aβ 42 ratios and amyloid PET imaging. Multivariable linear, logistic, Cox proportional hazards, and Fine–Gray competing-risk models were used. Results: HI was more prevalent among participants with mild cognitive impairment (MCI; defined as CDR = 0.5) than cognitively normal individuals (50% versus 24%, p < 0.001), and MCI status was independently associated with worse baseline WIN thresholds (β = 1.55 dB SNR; 95% CI 0.72–2.37). HI was not cross-sectionally associated with CSF amyloid or tau ratios or amyloid PET positivity. Longitudinally, baseline MCI was associated with a higher risk of incident HI (Cox HR = 2.63, 95% CI 1.48–4.67; Fine–Gray sHR = 2.79, 95% CI 1.06–7.40), whereas baseline HI was not associated with subsequent CDR progression. Conclusions: In older adults, HI was associated with MCI but not core AD biomarkers or future CDR progression, suggesting that late-life HI may reflect cognitive vulnerability or broader brain aging rather than independently driving AD pathology.
- 28 July 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (2) , 769-780
Hearing in noise and cognitive status in older adults: Biomarker associations and bidirectional survival analyses
Background: Hearing impairment (HI) has been identified as a potentially modifiable risk factor for dementia, yet its relationship with Alzheimer's disease (AD) neuropathology and the temporal directionality remain unclear, particularly in late life. Objective: To examine cross-sectional and longitudinal associations between HI, clinical cognitive status, and AD biomarkers in community-dwelling older adults. Methods: We included 474 DRIVES Project participants (mean age 73.5 ± 5.2 years). Hearing was assessed using the NIH Toolbox Words-in-Noise (WIN) test. Clinical cognitive status was assessed using Clinical Dementia Rating (CDR). AD biomarkers included cerebrospinal fluid (CSF) Aβ 42 /Aβ 40 , t-tau/Aβ 42 , and p-tau/Aβ 42 ratios and amyloid PET imaging. Multivariable linear, logistic, Cox proportional hazards, and Fine–Gray competing-risk models were used. Results: HI was more prevalent among participants with mild cognitive impairment (MCI; defined as CDR = 0.5) than cognitively normal individuals (50% versus 24%, p < 0.001), and MCI status was independently associated with worse baseline WIN thresholds (β = 1.55 dB SNR; 95% CI 0.72–2.37). HI was not cross-sectionally associated with CSF amyloid or tau ratios or amyloid PET positivity. Longitudinally, baseline MCI was associated with a higher risk of incident HI (Cox HR = 2.63, 95% CI 1.48–4.67; Fine–Gray sHR = 2.79, 95% CI 1.06–7.40), whereas baseline HI was not associated with subsequent CDR progression. Conclusions: In older adults, HI was associated with MCI but not core AD biomarkers or future CDR progression, suggesting that late-life HI may reflect cognitive vulnerability or broader brain aging rather than independently driving AD pathology.
- 27 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Differential associations of core and non-core plasma biomarkers with cognitive performance in Black adults
Background: Black adults experience disproportionately higher rates of Alzheimer's disease and related dementias (ADRD), yet remain underrepresented in blood-based biomarker research. Understanding how plasma biomarkers relate to cognitive performance is essential for equitable detection and monitoring of ADRD. Objective: We examined cross-sectional and longitudinal associations of both core and non-core plasma biomarkers and cognition in a community-based cohort of Black adults. Methods: Participants from the ARCHES study completed baseline plasma biomarker assessments and neuropsychological testing, including a Preclinical Alzheimer Cognitive Composite (PACC) score and the Montreal Cognitive Assessment (MoCA). Plasma biomarkers reflecting amyloid, tau, neurodegeneration, and astrocytic activation were quantified using immunoprecipitation–mass spectrometry and ultrasensitive immunoassay platforms. Linear regression was used to evaluate cross-sectional associations between biomarkers and cognition. Linear mixed-effects models examined whether baseline biomarker levels were associated with cognitive change over one year, adjusting for age, sex, and education. Results: The sample included 334 participants with a mean baseline age of 64.6 years (SD = 10.1; range, 45–92.9). Cross-sectionally, higher brain-derived phosphorylated tau 181 was associated with poorer MoCA score (p = 0.04), and neurofilament light chain (NfL) level was also associated with lower PACC score (p = 0.04). Longitudinally, higher baseline NfL and glial fibrillary acidic protein (GFAP) were associated with faster cognitive decline (p < 0.001 and p = 0.018). Conclusions: Non-core NfL and GFAP biomarkers are associated with both cross-sectional and longitudinal cognitive performance. These findings highlight the importance of inclusive biomarker research and suggest non-core biomarkers may be particularly informative for characterizing cognitive aging and decline in this population.
- 27 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Differential associations of core and non-core plasma biomarkers with cognitive performance in Black adults
Background: Black adults experience disproportionately higher rates of Alzheimer's disease and related dementias (ADRD), yet remain underrepresented in blood-based biomarker research. Understanding how plasma biomarkers relate to cognitive performance is essential for equitable detection and monitoring of ADRD. Objective: We examined cross-sectional and longitudinal associations of both core and non-core plasma biomarkers and cognition in a community-based cohort of Black adults. Methods: Participants from the ARCHES study completed baseline plasma biomarker assessments and neuropsychological testing, including a Preclinical Alzheimer Cognitive Composite (PACC) score and the Montreal Cognitive Assessment (MoCA). Plasma biomarkers reflecting amyloid, tau, neurodegeneration, and astrocytic activation were quantified using immunoprecipitation–mass spectrometry and ultrasensitive immunoassay platforms. Linear regression was used to evaluate cross-sectional associations between biomarkers and cognition. Linear mixed-effects models examined whether baseline biomarker levels were associated with cognitive change over one year, adjusting for age, sex, and education. Results: The sample included 334 participants with a mean baseline age of 64.6 years (SD = 10.1; range, 45–92.9). Cross-sectionally, higher brain-derived phosphorylated tau 181 was associated with poorer MoCA score (p = 0.04), and neurofilament light chain (NfL) level was also associated with lower PACC score (p = 0.04). Longitudinally, higher baseline NfL and glial fibrillary acidic protein (GFAP) were associated with faster cognitive decline (p < 0.001 and p = 0.018). Conclusions: Non-core NfL and GFAP biomarkers are associated with both cross-sectional and longitudinal cognitive performance. These findings highlight the importance of inclusive biomarker research and suggest non-core biomarkers may be particularly informative for characterizing cognitive aging and decline in this population.
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e104024
The associations between major depressive disorder, plasma biomarkers of Alzheimer's disease, and mild behavior impairment among older adults
Background: Biomarkers and neuropsychiatric symptoms (NPS) are two early indicators for identifying Alzheimer's disease (AD) and related dementias (ADRD). Major depressive disorder (MDD) shares NPS with ADRD, complicating diagnoses. Plasma biomarkers, while non‐invasive, require further investigation to confirm their accuracy and consistency. Although both plasma biomarkers and mild behavior impairment, a new measure of NPS, are independently associated with ADRD risk, their interrelationship, especially in individuals with MDD, needs further exploration. This study explored the cross‐sectional associations between plasma biomarkers and MBI among participants with and without an MDD diagnosis. Methods: Participants ( n = 334) were community‐dwelling residents aged 65 and older and cognitively normal based on the Clinical Dementia Rating (CDR = 0). NPS were assessed using the MBI checklist. Plasma biomarkers including Aβ 42 /Aβ 40 , ptau 181 /nptau 181 , and ptau 217 /nptau 217 were measured at C2N Diagnostics. MDD diagnoses were confirmed through medical records. Logistic regression models were used to evaluate the associations between MDD, plasma biomarkers, and MBI. The use of antidepressants and demographic variables were added to the models as control variables. Results: Among the 334 participants, 236 were non‐depressed, and 98 were from the MDD cohort. 188 (56.3%) were female. The average age was 74.6 years (SD = 5.39), and the average year of education was 16.6 (SD = 2.35). Of the participants, 38 (11.4%) self‐identified as Black or African American. There was no significant difference in race or education level between participants with and without an MDD diagnosis. Compared to participants with neither a MDD diagnosis nor Aβ 42 /Aβ 40 positivity, participants with MDD diagnoses and negative Aβ 42 /Aβ 40 were 5.42 (95% CI = 2.69–11.57) times more likely to endorse MBI symptoms. Participants with both MDD and Aβ 42 /Aβ 40 positivity were 7.23 (95% CI = 1.87–47.81) times more likely to endorse MBI symptoms. Conclusion: MDD is associated with a worsening of MBI. Early identification and management of MDD may help reduce NPS severity. Differentiating ADRD from other neuropsychiatric conditions, such as MDD, remains a challenge. Further research is needed to clarify the distinct diagnostic and behavioral characteristics of ADRD and MDD.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e104024
Open AccessThe associations between major depressive disorder, plasma biomarkers of Alzheimer's disease, and mild behavior impairment among older adults
Background: Biomarkers and neuropsychiatric symptoms (NPS) are two early indicators for identifying Alzheimer's disease (AD) and related dementias (ADRD). Major depressive disorder (MDD) shares NPS with ADRD, complicating diagnoses. Plasma biomarkers, while non‐invasive, require further investigation to confirm their accuracy and consistency. Although both plasma biomarkers and mild behavior impairment, a new measure of NPS, are independently associated with ADRD risk, their interrelationship, especially in individuals with MDD, needs further exploration. This study explored the cross‐sectional associations between plasma biomarkers and MBI among participants with and without an MDD diagnosis. Methods: Participants ( n = 334) were community‐dwelling residents aged 65 and older and cognitively normal based on the Clinical Dementia Rating (CDR = 0). NPS were assessed using the MBI checklist. Plasma biomarkers including Aβ 42 /Aβ 40 , ptau 181 /nptau 181 , and ptau 217 /nptau 217 were measured at C2N Diagnostics. MDD diagnoses were confirmed through medical records. Logistic regression models were used to evaluate the associations between MDD, plasma biomarkers, and MBI. The use of antidepressants and demographic variables were added to the models as control variables. Results: Among the 334 participants, 236 were non‐depressed, and 98 were from the MDD cohort. 188 (56.3%) were female. The average age was 74.6 years (SD = 5.39), and the average year of education was 16.6 (SD = 2.35). Of the participants, 38 (11.4%) self‐identified as Black or African American. There was no significant difference in race or education level between participants with and without an MDD diagnosis. Compared to participants with neither a MDD diagnosis nor Aβ 42 /Aβ 40 positivity, participants with MDD diagnoses and negative Aβ 42 /Aβ 40 were 5.42 (95% CI = 2.69–11.57) times more likely to endorse MBI symptoms. Participants with both MDD and Aβ 42 /Aβ 40 positivity were 7.23 (95% CI = 1.87–47.81) times more likely to endorse MBI symptoms. Conclusion: MDD is associated with a worsening of MBI. Early identification and management of MDD may help reduce NPS severity. Differentiating ADRD from other neuropsychiatric conditions, such as MDD, remains a challenge. Further research is needed to clarify the distinct diagnostic and behavioral characteristics of ADRD and MDD.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e104347
The Association between Cognitive Impairment, Structural and Social Determinants of Health, and Mood Disorder among Black Adults in the Greater St. Louis Metropolitan Area
Background: Black middle‐aged and older adults face a significantly higher risk of mood disorders and cognitive impairment compared to non‐Hispanic Whites. Prior evidence underscores that the structural and social determinants of health (S/SDOH) are estimated to contribute to 60‐80% of all health outcomes. However, evidence examining the intersection of S/SDOH and depression and anxiety remains fragmented, often focusing on limited measures like income or socioeconomic status or using aggregated measures at the census tract. This study utilized a new S/SDOH measure based on the National Institute on Aging Health Disparities Research Framework using individual and household level data to examine the relationship between mood disorders (depression and anxiety), cognitive impairment, and S/SDOH. Methods: Baseline data from Black participants aged 45 and older ( n = 312) in the Greater St. Louis Metropolitan region were examined. A S/SDOH composite index (S/SDOH‐CI) was constructed to measure participants' deprivation and unique risk factors. Depression and anxiety symptoms were measured using the Patient Health Questionnaire (PHQ‐9) and the Generalized Anxiety Disorder 7 item (GAD‐7). Cognitive impairment was assessed using the Montreal Cognitive Assessment (MoCA) and a preclinical Alzheimer's cognitive composite (PACC) score. Results: Among 312 cognitively normal participants, the average age was 64.5 (SD = 9.9), and the average education level was 15 years (SD = 2.82). 77.6% were female, and 108 (35%) had at least mild mood disorder symptoms. Logistic regression analysis indicated that a one SD increase in the burden of deprivation was associated with 3.12 times the odds of having any symptoms (95% CI: 2.13–4.92). Furthermore, contribution to S/SDOH‐CI revealed hardship and daily stressors (17%), and discrimination (11%) were the primary factors exacerbating mood disorders. These surpassed the contribution of education (10.67% [years and quality]), particularly among Black men, highlighting racism as a formidable driver of health inequities and lending additional evidence that there may be diminishing returns on human capital investments among Black men. Conclusion: These findings emphasize the need for medical advancements to progress together with social justice initiatives. The use of the S/SDOH‐CI uncovered within‐group differences and identified unique risk and resilience factors for mood disorders in Black older adults.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e104347
Open AccessThe Association between Cognitive Impairment, Structural and Social Determinants of Health, and Mood Disorder among Black Adults in the Greater St. Louis Metropolitan Area
Background: Black middle‐aged and older adults face a significantly higher risk of mood disorders and cognitive impairment compared to non‐Hispanic Whites. Prior evidence underscores that the structural and social determinants of health (S/SDOH) are estimated to contribute to 60‐80% of all health outcomes. However, evidence examining the intersection of S/SDOH and depression and anxiety remains fragmented, often focusing on limited measures like income or socioeconomic status or using aggregated measures at the census tract. This study utilized a new S/SDOH measure based on the National Institute on Aging Health Disparities Research Framework using individual and household level data to examine the relationship between mood disorders (depression and anxiety), cognitive impairment, and S/SDOH. Methods: Baseline data from Black participants aged 45 and older ( n = 312) in the Greater St. Louis Metropolitan region were examined. A S/SDOH composite index (S/SDOH‐CI) was constructed to measure participants' deprivation and unique risk factors. Depression and anxiety symptoms were measured using the Patient Health Questionnaire (PHQ‐9) and the Generalized Anxiety Disorder 7 item (GAD‐7). Cognitive impairment was assessed using the Montreal Cognitive Assessment (MoCA) and a preclinical Alzheimer's cognitive composite (PACC) score. Results: Among 312 cognitively normal participants, the average age was 64.5 (SD = 9.9), and the average education level was 15 years (SD = 2.82). 77.6% were female, and 108 (35%) had at least mild mood disorder symptoms. Logistic regression analysis indicated that a one SD increase in the burden of deprivation was associated with 3.12 times the odds of having any symptoms (95% CI: 2.13–4.92). Furthermore, contribution to S/SDOH‐CI revealed hardship and daily stressors (17%), and discrimination (11%) were the primary factors exacerbating mood disorders. These surpassed the contribution of education (10.67% [years and quality]), particularly among Black men, highlighting racism as a formidable driver of health inequities and lending additional evidence that there may be diminishing returns on human capital investments among Black men. Conclusion: These findings emphasize the need for medical advancements to progress together with social justice initiatives. The use of the S/SDOH‐CI uncovered within‐group differences and identified unique risk and resilience factors for mood disorders in Black older adults.
- 17 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (2) , 661-670
Hearing loss, plasma neurodegenerative biomarkers, and cognitive function: Independent and additive effects
Background: Hearing loss is one of the most prominent modifiable risk factors for dementia, accounting for one of the largest population-attributable risk among midlife exposures according to the Lancet Commission on Dementia. Plasma biomarkers such as neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau-217 (Ptau 217 ) have emerged as promising indicators of neurodegeneration and Alzheimer's disease (AD) pathology. Objective: To evaluate whether hearing loss and plasma biomarker concentrations are independently associated with cognitive function in aging adults, and to examine if these associations vary by age group. Methods: This cross-sectional study used data from 373 participants in the Aging Adult Brain Connectome (AABC) study. Hearing was assessed using the NIH Toolbox Words-in-Noise test, and cognitive function was measured by a Preclinical Alzheimer's Cognitive Composite (PACC). Plasma biomarkers included NfL, GFAP, total tau (tTau), and Ptau 217 . General linear models tested associations with cognition, adjusting for demographic, genetic, and cardiometabolic covariates. Interaction terms assessed modification by age and hearing. Results: Hearing loss was independently associated with lower PACC scores (β = −0.03, p < 0.001), after adjusting for covariates. Higher levels of NfL, GFAP, and Ptau 217 were each associated with worse cognition. Age significantly moderated these associations, with stronger biomarker–cognition links observed in adults aged 65 and older. No significant interactions were observed between hearing loss and plasma biomarkers. Conclusions: Hearing loss and plasma biomarkers reflect distinct, additive pathways of cognitive decline. These findings support integrated dementia risk models and highlight the potential of age- and biomarker-informed cognitive monitoring.
- 17 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (2) , 661-670
Hearing loss, plasma neurodegenerative biomarkers, and cognitive function: Independent and additive effects
Background: Hearing loss is one of the most prominent modifiable risk factors for dementia, accounting for one of the largest population-attributable risk among midlife exposures according to the Lancet Commission on Dementia. Plasma biomarkers such as neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau-217 (Ptau 217 ) have emerged as promising indicators of neurodegeneration and Alzheimer's disease (AD) pathology. Objective: To evaluate whether hearing loss and plasma biomarker concentrations are independently associated with cognitive function in aging adults, and to examine if these associations vary by age group. Methods: This cross-sectional study used data from 373 participants in the Aging Adult Brain Connectome (AABC) study. Hearing was assessed using the NIH Toolbox Words-in-Noise test, and cognitive function was measured by a Preclinical Alzheimer's Cognitive Composite (PACC). Plasma biomarkers included NfL, GFAP, total tau (tTau), and Ptau 217 . General linear models tested associations with cognition, adjusting for demographic, genetic, and cardiometabolic covariates. Interaction terms assessed modification by age and hearing. Results: Hearing loss was independently associated with lower PACC scores (β = −0.03, p < 0.001), after adjusting for covariates. Higher levels of NfL, GFAP, and Ptau 217 were each associated with worse cognition. Age significantly moderated these associations, with stronger biomarker–cognition links observed in adults aged 65 and older. No significant interactions were observed between hearing loss and plasma biomarkers. Conclusions: Hearing loss and plasma biomarkers reflect distinct, additive pathways of cognitive decline. These findings support integrated dementia risk models and highlight the potential of age- and biomarker-informed cognitive monitoring.
- 10 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (3) , 1143-1153
The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline
Background: Identifying predictive biomarkers of cognitive decline is critical for timely intervention in early Alzheimer's disease and related dementia. Biomarkers such as cerebrospinal fluid (CSF) neurofilament light (NfL), and MRI-based hippocampal atrophy are potential indicators of neurodegeneration, but their long-term predictive value remains unclear. Objective: This study examined 20-year longitudinal associations between CSF NfL, MRI-based hippocampal atrophy, and cognitive decline in cognitively normal older adults. Methods: A cohort of 279 cognitively normal adults aged ≥55 years was followed from 2003 to 2023 at the Knight ADRC. Participants underwent annual cognitive and neurological assessments, including Clinical Dementia Rating (CDR), CSF NfL quantification, and MRI-based hippocampal volumetry. Cognitive decline was defined as: (1) first progression (CDR ≥ 0.5) and (2) sustained progression (two consecutive CDRs ≥ 0.5). Analyses included Kaplan-Meier survival, Cox proportional hazards models, and linear mixed-effects (LME) models. Results: Participants had a mean age of 66.5 years (SD = 6.08); 58.4% were female. Mean follow-up was 11.41 years (SD = 3.5). First progression occurred in 71 participants (25.4%), and sustained progression in 35 (13%). Higher CSF NfL levels were associated with faster time to first (95% CI:0.2–1; p < 0.001) and sustained progression (95% CI:0.46–1; p = 0.008). Cox models showed increased risk of first progression (HR = 1.83; 95% CI: 1.11–3.01; p = 0.018) but not sustained (p = 0.093). LME models showed CSF NfL increase and hippocampal volume decline (p < 0.001) in both outcomes. Conclusions: CSF NfL is a strong predictor of cognitive decline and may serve as a screening biomarker for early dementia risk.
- 10 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (3) , 1143-1153
The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline
Background: Identifying predictive biomarkers of cognitive decline is critical for timely intervention in early Alzheimer's disease and related dementia. Biomarkers such as cerebrospinal fluid (CSF) neurofilament light (NfL), and MRI-based hippocampal atrophy are potential indicators of neurodegeneration, but their long-term predictive value remains unclear. Objective: This study examined 20-year longitudinal associations between CSF NfL, MRI-based hippocampal atrophy, and cognitive decline in cognitively normal older adults. Methods: A cohort of 279 cognitively normal adults aged ≥55 years was followed from 2003 to 2023 at the Knight ADRC. Participants underwent annual cognitive and neurological assessments, including Clinical Dementia Rating (CDR), CSF NfL quantification, and MRI-based hippocampal volumetry. Cognitive decline was defined as: (1) first progression (CDR ≥ 0.5) and (2) sustained progression (two consecutive CDRs ≥ 0.5). Analyses included Kaplan-Meier survival, Cox proportional hazards models, and linear mixed-effects (LME) models. Results: Participants had a mean age of 66.5 years (SD = 6.08); 58.4% were female. Mean follow-up was 11.41 years (SD = 3.5). First progression occurred in 71 participants (25.4%), and sustained progression in 35 (13%). Higher CSF NfL levels were associated with faster time to first (95% CI:0.2–1; p < 0.001) and sustained progression (95% CI:0.46–1; p = 0.008). Cox models showed increased risk of first progression (HR = 1.83; 95% CI: 1.11–3.01; p = 0.018) but not sustained (p = 0.093). LME models showed CSF NfL increase and hippocampal volume decline (p < 0.001) in both outcomes. Conclusions: CSF NfL is a strong predictor of cognitive decline and may serve as a screening biomarker for early dementia risk.
- 21 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 3-14
The effect of anti-seizure medications on Alzheimer's disease (AD) risk and AD-related symptoms: A scoping review
Background: As the fastest-growing segment of the population, adults over 65 are at the most significant risk for Alzheimer's disease (AD). Older adults often use anti-seizure medications (ASMs), which can negatively impact cognitive function, mood, and behavior, mimicking AD or its symptoms. Understanding the effects of ASMs across diverse older adults is crucial, given that some ethnoracial groups are at higher risk for AD or more severe symptoms compared to non-Hispanic Whites. Objective: To summarize the current evidence on the association of ASMs with AD risk and AD-related symptoms and explore the inclusion of ethnoracial minority groups in these studies. Methods: Data sources included PubMed/MEDLINE, EMBASE, and SCOPUS for English-language studies published between 1990–2024. Selected studies were peer-reviewed, cross-sectional, longitudinal, case-control, and clinical trials on AD dementia or related symptoms and ASMs. Study quality was rated by the Oxford Centre for Evidence-Based Research Medicine. Results: A total of 27 studies with 1,241,796 participants were included. Data on AD risk from level IB-IIIB evidence studies showed mixed results, with some indicating an increased association with ASM use [OR = 1.05–1.16, 95% CI: 1.01–1.24]. Studies on AD-related symptoms from level IB-IV evidence also showed mixed results. Only three North American studies explicitly included race/ethnicity; most were conducted in European countries. Conclusions: ASM use may be modestly associated with an increased risk of AD among the older adult population, but current data are inconclusive. The association of ASMs on AD-related symptoms varied. Future studies should emphasize reporting sociodemographic data and include diverse cohorts to enhance the applicability of findings.
- 21 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 3-14
The effect of anti-seizure medications on Alzheimer's disease (AD) risk and AD-related symptoms: A scoping review
Background: As the fastest-growing segment of the population, adults over 65 are at the most significant risk for Alzheimer's disease (AD). Older adults often use anti-seizure medications (ASMs), which can negatively impact cognitive function, mood, and behavior, mimicking AD or its symptoms. Understanding the effects of ASMs across diverse older adults is crucial, given that some ethnoracial groups are at higher risk for AD or more severe symptoms compared to non-Hispanic Whites. Objective: To summarize the current evidence on the association of ASMs with AD risk and AD-related symptoms and explore the inclusion of ethnoracial minority groups in these studies. Methods: Data sources included PubMed/MEDLINE, EMBASE, and SCOPUS for English-language studies published between 1990–2024. Selected studies were peer-reviewed, cross-sectional, longitudinal, case-control, and clinical trials on AD dementia or related symptoms and ASMs. Study quality was rated by the Oxford Centre for Evidence-Based Research Medicine. Results: A total of 27 studies with 1,241,796 participants were included. Data on AD risk from level IB-IIIB evidence studies showed mixed results, with some indicating an increased association with ASM use [OR = 1.05–1.16, 95% CI: 1.01–1.24]. Studies on AD-related symptoms from level IB-IV evidence also showed mixed results. Only three North American studies explicitly included race/ethnicity; most were conducted in European countries. Conclusions: ASM use may be modestly associated with an increased risk of AD among the older adult population, but current data are inconclusive. The association of ASMs on AD-related symptoms varied. Future studies should emphasize reporting sociodemographic data and include diverse cohorts to enhance the applicability of findings.